All In Biotech

Drug Trial Radar · NCT05493800

Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT

A Phase IIa, Multi-center, Dose-finding Study to Evaluate Safety and Efficacy for Prevention of Oral Mucositis and PK of MIT-001 in Patients With Lymphoma or Multiple Myeloma Receiving Conditioning Chemotherapy Followed by Auto HSCT

Last checked: Nov 19, 2026Latest source record: May 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Feb 1, 2022

Primary completion

Jun 30, 2024

Study completion Dec 30, 2024

Sponsor

Lead sponsor
MitoImmune TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the efficacy and safety for the prevention of oral mucositis and PK of MIT-001 for lymphoma or multiple myeloma patients receiving conditioning chemotherapy for autologous hematopoietic stem cell transplantation(auto-HSCT).

Conditions

  • Oral Mucositis
  • Lymphoma
  • Multiple Myeloma
  • Hematologic Cancer

Interventions

  • MIT-001Drug

    Corresponding dose of MIT-001 IV injection during 0.5\~1hr

  • normal salineDrug

    normal saline IV injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of Severe Oral Mucositis(SOM).Time frame: up to 14 days after the end of therapy( or discharge if hospitalization extension is necessary)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Seoul ST. Mary's Hospital

    Seoul, South Korea

  • Yeouido ST. Mary's Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.